Drug
Vandetanib clinical trials
Also written Zactima, ZD6474, Caprelsa and SAR390530.
- studies test it
- 99
- open now
- 1
- in phase 3
- 6
- first study started
- 2002
Keep track of what changes. Save the vandetanib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
99 studies that test it; most in 2008 (20)
| Year | Studies |
|---|---|
| 2002 | 3 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 14 |
| 2007 | 19 |
| 2008 | 20 |
| 2009 | 8 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 9 |
| 2013 | 4 |
| 2014 | 5 |
| 2015 | 3 |
| 2018 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 40
- Phase 2
- 55
- Phase 3
- 6
- Phase 4
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 42 · Other 57
Genzyme, a Sanofi Company (35) · National Cancer Institute (NCI) (8) · Sanofi (7) · M.D. Anderson Cancer Center (5) · Dana-Farber Cancer Institute (4) · UNICANCER (2) · Samsung Medical Center (2) · SWOG Cancer Research Network (2)
Often tested with
Tested in the same studies.
Carboplatin (5) · Everolimus (4) · Gemcitabine (4) · AZD 6244 (3) · Paclitaxel (3) · Docetaxel (3) · Oxaliplatin (3) · Imatinib (3)
Studies
Open first, then newest update. How each study uses vandetanib is read from its arms, and is right about nine times in ten.
Testing it · 99
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingPhase 2West China HospitalNCT06482086Written as Vandetanib
- Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT01582191Written as Vandetanib
- To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid CancerCompletedPhase 4SanofiNCT01496313Written as 300mg vandetanib
- An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerCompletedPhase 3Genzyme, a Sanofi CompanyNCT00410761Written as ZD6474 (Vandetanib)
- Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic CarcinomaCompletedPhase 2University of LiverpoolNCT01601808Written as Caprelsa (vandetanib)
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingPhase 2UNICANCERNCT02299999Written as Vandetanib
- Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC PatientsCompletedPhase 3Genzyme, a Sanofi CompanyNCT00418886Written as Vandetanib
- Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid CancerCompletedPhase 3Genzyme, a Sanofi CompanyNCT01876784Written as Vandetanib (SAR390530)
- Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid CancerCompletedPhase 2Genzyme, a Sanofi CompanyNCT00537095Written as Vandetanib
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedPhase 2UNICANCERNCT02117167Written as Vandetanib
- Effect of Vandetanib on Cellular Markers in Invasive Breast CancerTerminatedPhase 2Ronald WeigelNCT01934335Written as Vandetanib
- A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)CompletedPhase 1Cancer Research UKNCT01586624Written as Vandetanib, Selumetinib
- Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid CancerTerminatedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT03630120Written as Vandetanib
- Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell CarcinomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT02495103Written as Vandetanib
- A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by SurgeryCompletedPhase 1Fox Chase Cancer CenterNCT01183559Written as Vandetanib
- Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck LesionsCompletedPhase 2University of ChicagoNCT01414426Written as vandetanib
- Vandetanib to Treat Children and Adolescents With Medullary Thyroid CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT00514046Written as Vandetanib
- Vandetanib in Advanced NSCLC With RET RearrangementCompletedPhase 2Samsung Medical CenterNCT01823068Written as Vandetanib
- HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)Status unknownNot applicableAmsterdam UMC, location VUmcNCT02239952Written as vandetanib
- Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal TumorsCompletedPhase 2National Cancer Institute (NCI)NCT02015065Written as Vandetanib
See all 99 studies that test vandetanib →
Given in every arm · 4 — vandetanib is usual care beside what is tested
- Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib TreatmentCompletedPhase 3SanofiNCT01298323Written as Vandetanib
- A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)TerminatedPhase 1/2National Cancer Institute (NCI)NCT00923247Written as Vandetanib
- Open Label, Phase I ZD6474 Head and Neck Cancer StudyCompletedPhase 1SanofiNCT00450138Written as ZD6474 (vandetanib)
- Phase II Study of ZD6474 in Advanced NSCLCTerminatedPhase 2M.D. Anderson Cancer CenterNCT00290537Written as ZD6474
As the comparator · 2 — what is tested is compared with vandetanib
- A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerActive, not recruitingPhase 3Loxo Oncology, Inc.NCT04211337Written as Vandetanib
- A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).WithdrawnPhase 3Hoffmann-La RocheNCT04760288Written as Vandetanib
Codes
What other systems call vandetanib · ClinicalTrials.gg INT004437
- MeSH (NLM) C452423vandetanibConfirmed NLM, Wikidata
- UNII (FDA) YO460OQ37KVANDETANIBConfirmed FDA, NLM, Wikidata
- RxNorm 1098413Confirmed FDA, Wikidata
- Wikidata Q7914515vandetanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2737VandetanibOne source FDA
- DrugBank DB05294One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C452423 | vandetanib | Confirmed NLM, Wikidata |
| UNII (FDA) | YO460OQ37K | VANDETANIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1098413 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7914515 | vandetanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2737 | Vandetanib | One source FDA |
| DrugBank | DB05294 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.